Drug Profile
Gemtuzumab ozogamicin - Pfizer
Alternative Names: Anti-CD33-monoclonal-antibody-calicheamicin; Anti-CD33-monoclonal-antibody-p67-6-calicheamicin-conjugate; CDP-771; CMA-676; Gemtuzumab; HP67-6-N-acetyl-gamma-dimethyl-acbut; Human-anti-CD33-monoclonal-antibody-P67-6-calicheamicin-conjugate; MYLOTARG; Mylotarg; WAY-CMA-676Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator UCB
- Developer National Cancer Institute (USA); Pfizer; Technische Universitat Dresden
- Class Aminoglycosides; Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia
Most Recent Events
- 27 Apr 2023 9387040- No updates
- 31 Mar 2023 Pfizer completes a phase III trial in Acute myeloid leukaemia (Combination therapy, In children, In adolescents, Second-line therapy or greater) in United Kingdom, Switzerland, Sweden, Spain, Slovenia, Slovakia, Netherlands, Italy, Ireland, Hungary, Germany, France, Finland, Denmark, Czech Republic, Belgium, Austria (IV) (ISRCTN14207975)
- 17 May 2022 OHSU Knight Cancer Institute and Pfizer re-initiates enrolment in a phase I trial for Acute myeloid leukemia (Combination therapy, Newly diagnosed, First-line therapy) in the US (NCT03900949)